PACIFICO Yokohama, Japan      October 13 (Wed.) – 15 (Fri.), 2021


Oct.13(Wed.)      10  :  00  ~  11  :  30

F203-206
【K-1】 Keynote Lecture
Pre-Registration required Simultaneous interpretation Video Archive available after Exhibition (subject to a fee)

Keynote Lecture 

Challenges & Prospects of Japan's STI Policy Toward Realizing Society 5.0

Koichi AKAISHI

Vice-Minister for Digital Policy
Digital Agency

Japanese

【Remote Presentation】
The world is moving towards "Public Interest".

George Hara

Chairman of the Board, Alliance Forum Foundation / Group Chairman and CEO, DEFTA Partners

Japanese

"Current status and issues of infection control in Japan" - COVID-19 as an example -

Isao Teshirogi, Ph.D.

President and CEO
Shionogi & Co., Ltd.

Japanese


Partnering Participants: Free
Visitor registration only: ¥10,000

【S-21】 Noster Inc.
Pre-Registration required Simultaneous interpretation Online Seminar

Future technologies to deepen gut microbiome research 

With the progress of genome science, the study of gut microorganisms has shifted from isolation and identification to a bird's eye view of the microbiota and microbiome. In the future, the knowledge of intestinal microbiota and diseases and health will be further deepened through genomic analysis at the single-cell level, metabolomics analysis of a vast number of molecules, and information science such as cohort studies to reveal the relationship between health conditions and diseases and intestinal microbiota. In this seminar, we would like to introduce examples of these research together with research that develop functional molecules and functional microorganisms as concrete tools with an example of probiotics, HYA, development and discuss future trends in gut microbial research.

Gut microbiome research with omics and information sciences and what links them -progress in postbiotics, HYA, development-

Prof. Ogawa Jun

Professor
Division of Applied Life Sciences, Graduate School of Agriculture
Kyoto University

Japanese

Advanced lipidomics technology and its application to elucidate the complex lipid diversity of the gut ecosystem

Prof. Arita Makoto

Professor
Division of Physiological Chemistry and Metabolism, Faculty of Pharmacy
Keio University

Japanese

Noster company’s information

Dr. Yonejima Yasunori

Research Manager
Microbiome group, R&D Divisoin
Noster Inc.

Japanese


【S-22】 Bayer Yakuhin, Ltd.
Pre-Registration required Online Seminar

Research and Development Strategy and Open Innovation at Bayer 

Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Pharmaceuticals Division at Bayer is globally conducting research and development activities with the goal of delivering innovative prescription drugs to patients, focusing on the fields of cardiovascular and nephrology, oncology, ophthalmology, gynecology, hematology, and diagnostic imaging.

In addition, Bayer has been promoting open innovation in Japan as one of its key innovation sources since establishing the Open Innovation Center in Japan in 2014. Currently, Bayer has established partnerships with several universities and startup companies and is actively engaged in the creation of innovations through "co-creation" in the field of new modalities and digital technologies. At the same time, Bayer is also working on fostering an innovation ecosystem centered around CoLaborator Kobe, a startup incubator Bayer opened in Kobe in 2018, in close collaboration with a broad spectrum of external stakeholders.

In this seminar, Dr. Christian Rommel, Head of Research and Development of Pharmaceuticals at Bayer AG, will introduce the global R&D strategy in drug development, followed by a presentation on open innovation initiatives in Japan by Shunichi Takahashi, Head of Open Innovation Center Japan at Bayer Yakuhin.

Bayer Pharmaceuticals’ Approach to Innovation

Dr. Christian Rommel

Head of Research & Development and Member of Executive Committee of Bayer AG Pharmaceuticals
Bayer AG


Oct.13(Wed.)      11  :  30  ~  12  :  30

F201-202
【L-1】 TAKARA BIO INC.
Pre-Registration required

The latest trends in development of the next generation CAR-T 

Coordinator

Dr. Mineno Junichi

Senior Corporate Officer & COO
TAKARA BIO INC.

Dr. Kagoya Yuki

Chief
Division of Immune Response
Aichi Cancer Center Research Institute

Japanese

Mr. Masanobu Kimura

Takara Bio Inc.

Japanese


Oct.13(Wed.)      13  :  00  ~  14  :  00

F201-202
【S-1】 Takeda Pharmaceutical Company Limited
Pre-Registration required

The Future of Cancer Treatment and Healthcare Shaped by Technology and Data Science 

This seminar will highlight the commitment of Takeda's Japan Oncology business to improve treatment outcomes for cancer patients through partnerships.

Following short presentations by the National Cancer Center Hospital East on cancer treatments based on data science, and Mitsui Fudosan on developing cities of the future based on problem-solving for improving well-being, there will be a discussion on "the future of cancer treatment and healthcare," including how to provide new medical solutions from the perspectives of industry and academia.

Coordinator

Mr. Takafumi Horii

Senior Vice President, Head of Japan Oncology Business Unit
Japan Oncology Business Unit, Global Oncology Business Unit
Takeda Pharmaceutical Company Limited

Creating the future of cancer treatments based on data science

Dr. Katsuya Tsuchihara

Chief, Division of Translational Informatics
Exploratory Oncology Research & Clinical Trial Center
National Cancer Center

Japanese

Developing a new city based on problem-solving to enhance well-being

Mr. Kazunori Yamashita

Managing Officer, General Manager
Kashiwanoha Urban Planning and Development Department
Mitsui Fudosan Co., Ltd.

Japanese

Contributing to the improvement of cancer patient treatment outcomes

Dr. Jumpei Soeda

Head
Medical Affairs, Japan Oncology Business Unit
Takeda Pharmaceutical Company Limited

Japanese

Panel Discussion

Ms. Yukiko Sakakibara

Head
Strategic Portfolio Planning, Japan Oncology Business Unit
Takeda Pharmaceutical Company Limited

Japanese


Oct.13(Wed.)      13  :  00  ~  14  :  00

F203-204
【S-2】 BASF Japan Ltd.
Pre-Registration required

BASF Japan Ltd. Sponsored Seminar 

We will hold a collaboration seminar with Professor Satoshi Yamazaki of University of Tsukuba. BASF will present new solutions for BASF pharmaceutical excipients for cell culture, and Professor Satoshi Yamazaki will present about "Development of expansion technology for haematopoietic-stem-cell and its clinical application". In this presentation, Professor Satoshi Yamazaki will share innovative results on ex vivo haematopoietic-stem-cell expansion using BASF polymer. Please join our seminar and feel the fusion of chemistry and biology!

Introduction of new solutions for BASF pharmaceutical excipients for cell culture

Mr. Tsubasa Sano

Technical Service
Pharma Solutions, Nutrition & Health
BASF Japan Ltd.,

Japanese

Development of expansion technology for hematopoietic stem cells and its clinical application

Prof. Satoshi Yamazaki

Professor
Laboratory of Stem Cell Therapy, Faculty of Medicine
University of Tsukuba

Japanese


Oct.13(Wed.)      14  :  30  ~  15  :  30

F203-204
【S-9】 INFOCOM CORPORATION / H1 Insights,Inc.
Pre-Registration required

Supporting digital transformation in the healthcare industry ~ Introduction of world's largest KOL database ~ 

Supporting the Digital Transformation of the Healthcare Industry - Action of Infocom and H1 Insights

Hideakii Kaji

Infocom Corporation

Japanese

How to Optimize KOL Engagement in the Digitalized World

Ms. Yuki Wick

Customer Success Manager
H1 Insights, Inc.

Japanese

Infocom Solutions and Case Study with H1 Data.

Eiji Yamabe

Infocom Corporation

Japanese


Oct.13(Wed.)      16  :  00  ~  17  :  00

F205-206
【S-6】 MEDICAL & BIOLOGICAL LABORATORIES CO., LTD.
Pre-Registration required

Drug Discovery Services of JSR Life Sciences Group 

JSR Life Sciences brings together the deep biochemical knowledge and understanding of human disease, expertise in drug discovery and development, and access to capital into a single, integrated framework that creates value for our customers. We will introduce our recent challenges with new products and services of JLS group companies, MBL and Crown Bioscience.
MBL has more than 30 years of experience in developing monoclonal antibodies and leading IVD reagents in Japan. We are promoting the iMADE project in order to provide its expertise in antibody development to more unmet needs in the early stage of development. In this seminar, we will introduce the open innovation and development platform that MBL is aiming for.
Crown Bioscience will provide a general view of current development of the animal modeling for oncology discovery. The future of cancer therapy, including immunotherapy, lies in personalized treatment. Patient-derived xenograft (PDX) models, mouse clinical trial platforms, as well as immune-oncology animal modeling related syngeneic homograft, GEMM-derived MuPrime homograft, chimeric humanized HuGEMM and HuCELL models, and humanized mouse models provide comprehensive animal models targeting different cancer drug related strategies, helping drug development in cancer.

Strategies for Antibody-Drug Discovery Support

Mr. Jun-ichi Akatsuka

MEDICAL & BIOLOGICAL LABORATORIES CO., LTD.

Japanese

New Innovation of Animal Modeling for Oncology Drug Discovery

Dr. Jessie Wang

Senior Director
Department of Cancer Pharmacology
Crown Bioscience Inc.


Oct.13(Wed.)      16  :  00  ~  17  :  00

F203-204
【S-18】 Chugai Pharmaceutical Co., Ltd.
Pre-Registration required Simultaneous interpretation

Chugai Pharmaceutical Co., Ltd. 

Open innovation in Chugai and comprehensive collaboration between IFReC

Mr. Kunihiro Hattori

Associate Vice President, Senior Fellow in Research Div.
Chugai Pharmaceutical Co., Ltd.

Japanese

Functional genome analysis of immune-mediated diseases for drug discovery

Mr. Hiroyuki Tsunoda

Head of Discovery Technology Dept.
Chugai Pharmaceutical Co., Ltd.

Japanese

Open innovation practice to realize integrated continuous biomanufacturing – Collaboration of Chugai and Cytiva

Mr. Takuo Kawase

Head of Bio 6 Group in API Process Development Dept.
Chugai Pharmaceutical Co., Ltd.

Japanese


Oct.14(Thu.)      10  :  00  ~  11  :  00

F203-204
【S-7】 Thermo Fisher Scientific (Patheon)
Pre-Registration required

New Drug Modalities ( Plasmid DNA/ Viral Vector / mRNA) CDMO services updates
 

Mr. Koji Tanimoto

Senior Director, Head of Business Development, Asia Pacific
Thermo Fisher Scientific, Pharma Services

Japanese

Building viral vector capacity and capabilities to realize the promise of gene therapies

Mr. Chris Murphy

Vice President and General Manager, Viral Vector Services
Thermo Fisher Scientific, Pharma Services (Patheon)

Addressing technical and manufacturing challenges in mRNA platform

Ms. Vincenza Pironti, PhD

Global SME, Sterile Drug Products
Thermo Fisher Scientific, Pharma Services (Patheon)


Oct.14(Thu.)      10  :  00  ~  11  :  30

G401-402
【O-7】
Pre-Registration required

 

Coordinator

Kohei Tsumoto

Biotherapies as protectors of Japan Health and Economy – 5 factors to garner its power

Mr. Stephane Perrey

General Manager Japan
Cytiva Japan

Japanese

Supply chain management as a global CDMO during the COVID-19 pandemic and our future direction

Dr. Murata Hiroshi

Executive Director
Life Science Div.
AGC Inc. Chemical Company

Japanese

Correcting imbalances among Technology, Business Development, and Regulatory Strategy & Internationalization - Toward Strengthening the Resilience of the Japanese Biopharmaceutical Industry-

Dr. Fumiaki Yumoto

Representative Director
Ginward Japan K.K.

Japanese

Strategy for building resilience in biotech supply chains

Mr. Kozo Saiki

Director, Bio-Industry Division
Commerce and Service Industry Policy Group
Ministry of Economy, Trade and Industry

Japanese

the reinforcement of Bio-product supply chains

Kyowa Kirin Co., Ltd

Japanese


Oct.14(Thu.)      10  :  30  ~  11  :  30

F201-202
【S-8】 Kyoto University Medical Science and Business Liaison Organization
Pre-Registration required

Fireside Chat: Kyoto University's Collaboration with a Foreign Pharmaceutical Company 

Industry-academia collaboration is essential for universities to create innovations and implement them in society. However, in a recent internal survey at Kyoto University, a certain number of researchers answered that they were interested in industry-university collaboration but had no experience in it. The most common reason for this was anxiety for communication with companies.

One of the factors that make such communication difficult is due to unsureness how to handle "secrets" between academia and pharma. Academia side is concerned about the risk of companies exploiting important information unconsciously during communication, and companies are also concerned about the risk of internal information "contamination" by obtaining information from universities, and also the risk of leaking confidential information by universities provided by companies. This difficulty in communication becomes a major issue in industry-academia collaboration.

Kyoto University has comprehensive collaborative relationships with three foreign pharmaceutical companies, Bayer, Boehringer Ingelheim, and J&J Innovation, respectively. Although the communication with foreign companies is more difficult for Japanese academia due to the language difference, we all device and carry out various alliance activities. In this seminar, we will discuss these issues and propose solutions with panelists from three companies deeply involved in global alliance activities.

Coordinator

Dr. Shinobu Suzuki

Professor
Medical Science and Business Liaison Organization
Kyoto University, Graduate School of Medicine

Dr. Shunichi Takahashi

Head of Open Innovation Center Japan
Bayer Yakuhin, Ltd.

Japanese

Dr. Tomoko Maeda

Head
Research Beyond Borders Japan
Nippon Boehringer Ingelheim

Japanese

Dr. Jun Kusunoki

Director
Johnson & Johnson Innovation

Japanese


Oct.14(Thu.)      12  :  00  ~  13  :  00

F203-204
【L-2】 LEO Pharma
Pre-Registration required Simultaneous interpretation

Innovation Ecosystem driven by LEO Pharma, Venture Cafe Tokyo & CIC Tokyo 

Welcome & Introduction of LEO Pharma

Dr. Tord Labuda

President and Representative Director
LEO Pharma

LEO Pharma's ecosystem creation that enables future innovation

Dr. Taruho Kuroda

Senior Director
LEO Science & Tech Hub
LEO Pharma

Japanese

Venture Café Tokyo & its social impact "creating a true innovation community"

Mr. Ryusuke Komura

Program Director
Venture Cafe Tokyo

Japanese

Looking back the 1st year of CIC Tokyo, the largest innovation hub in Tokyo originated in Boston

Dr. Masaru Nagura

General Manager
CIC Japan

Japanese

Panel Discussion

Taruho Kuroda / Ryusuke Komura / Masaru Nagura

Japanese


Oct.14(Thu.)      13  :  30  ~  14  :  30

F201-202
【S-10】 TAKARA BIO INC.
Pre-Registration required

TAKARA BIO INC. 

Coordinator

Dr. Mineno Junichi

Senior Corporate Officer & COO
TAKARA BIO INC.

Prof. Nakai Hiroyuki

School of Medicine Distinguished Professor in Molecular Medicine, Molecular and Medical Genetics, School of Medicine
Oregon Health & Science University

Japanese

Dr. Mineno Junichi

Takara Bio Inc.

Japanese


Oct.14(Thu.)      15  :  00  ~  16  :  00

F203-204
【S-13】 Bayer Yakuhin, Ltd.
Pre-Registration required Simultaneous interpretation

Research and Development Strategy and Open Innovation at Bayer 

Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Pharmaceuticals Division at Bayer is globally conducting research and development activities with the goal of delivering innovative prescription drugs to patients, focusing on the fields of cardiovascular and nephrology, oncology, ophthalmology, gynecology, hematology, and diagnostic imaging.

In addition, Bayer has been promoting open innovation in Japan as one of its key innovation sources since establishing the Open Innovation Center in Japan in 2014. Currently, Bayer has established partnerships with several universities and startup companies and is actively engaged in the creation of innovations through "co-creation" in the field of new modalities and digital technologies. At the same time, Bayer is also working on fostering an innovation ecosystem centered around CoLaborator Kobe, a startup incubator Bayer opened in Kobe in 2018, in close collaboration with a broad spectrum of external stakeholders.

In this seminar, Dr. Christian Rommel, Head of Research and Development of Pharmaceuticals at Bayer AG, will introduce the global R&D strategy in drug development, followed by a presentation on open innovation initiatives in Japan by Shunichi Takahashi, Head of Open Innovation Center Japan at Bayer Yakuhin.

(PP-OTH-JP-0477-12-08)

Coordinator

Dr. Ikuo Hayashi

Alliance Manager
Open Innovation Center Japan
Bayer Yakuhin, Ltd.

Bayer Pharmaceuticals’ Approach to Innovation

Dr. Christian Rommel

Head of Research & Development and Member of the Executive Committee of Bayer AG Pharmaceuticals
Bayer AG

Open Innovation at Bayer in Japan

Dr. Shunichi Takahashi

Head of Open Innovation Center Japan
Open Innovation Center Japan
Bayer Yakuhin, Ltd.

Japanese


Oct.14(Thu.)      15  :  00  ~  16  :  30

G401-402
【O-9】
Pre-Registration required

Strengthening the manufacturing base for next-generation biologics in Japan 

Coordinator

Prof. Kazuhisa Uchida

Professor
Guraduate School of Science, Technorlogy and Innovation
Kobe University

Strategy to strengthen manufacturing technology for next generation biologics in Daiichi Sankyo

Dr. Masayuki Yabuta

Biologics Division
Daiichi Sankyo Co., Ltd.

Japanese

Takara Bio, the company's initiative as a CDMO for Gene Therapy

Dr. Mineno Junichi

Senior Corporate Officer &COO
TAKARA BIO INC

Japanese

AGC’s initiatives for next generation biopharmaceutical manufacturing in Japan, US and EU

Mr. Noriyuki Komuro

Executive Officer, General Manager
Chemicals Company Life Science Division
AGC Inc.

Japanese

Proposal from Academia CPC

Dr. OKAZAKI Toshihiko

Associate professor
Medical Center for Translational and Clinical Research
OSAKA UNIVERSITY HOSPITAL

Japanese


Oct.14(Thu.)      16  :  00  ~  17  :  00

F205-206
【S-14】 Okinawa Science and Technology Promotion Center
Pre-Registration required

Infectious Disease Research in Okinawa: Introducing high-throughput biotechnology and its innovative products for infectious disease control 

Application of "camelid VHH antibody" and "natural bacteriophage" for infectious disease control.

Dr. Akikazu Murakami

Chief Executive Officer
RePHAGEN Co., Ltd.

Japanese

Vaccine development for infectious diseases of animals and fishes

Prof. Takeshi Arakawa

CEO
Jectas Innovators Company Limited

Japanese

Development of antibody test kit to evaluate efficacy after COVID-19 vaccination

Prof. Masaaki Ito

CEO
Silk Renaissance Co., Ltd.

Japanese


Oct.15(Fri.)      9  :  30  ~  11  :  00

F205-206
【O-12】 Challenges revealed by COVID-19 - Tackling the next pandemic -
Pre-Registration required Video Archive available after Exhibition (subject to a fee)

Challenges revealed by COVID-19 - Tackling the next pandemic - 

COVID-19 changed our daily lives and at the same time revealed various problems. Instead of leaving these as issues, we have to prepare for the next by recognizing them again. In this session, each expert will be on stage to talk about the issues and countermeasures for infectious diseases that have become apparent due to COVID-19.

Coordinator

Dr. Ohmagari Norio

Director, Disease Control and Prevention Center
Disease Control and Prevention Center
National Center for Global Health and Medicine

Ethical, legal and social implications on COVID-19

Prof. Kaori Muto

Professor
Department of Public Policy
The Institute of Medical Science, The University of Tokyo

Japanese

Mr. Hidetaka Nishimura

Deputy Director-General
National Healthcare Policy Secretariat
Cabinet Office, Government of Japan

Japanese

【Remote Presentation】
Challenge of DNA Vaccine to Infectious Disease

Prof. RYUICHI MORISHITA

Professor
Department of Clinical Gene Therapy
Osaka University

Japanese

A New Funding Scheme to Support Vaccine Research and Development in Japan

Mr. Katsufumi JO

Executive Director
Japan Agency for Medical Research and Development

Japanese


Partnering Participants: Free
Visitor registration only: ¥10,000

Oct.15(Fri.)      13  :  00  ~  14  :  30

F201-202
【O-15】 What is necessary to continuously develop new modalities from Japan?
Pre-Registration required

What is necessary to continuously develop new modalities from Japan? 

Coordinator

Mr. MASANOBU KIMURA

Director, Senior Executive Officer, Head of Regulatory and Quality Assurance Headquarters
TAKARA BIO INC.

Evolution and future possibilities of vector technology for gene and cell therapy

Prof. Takashi Okada

Professor
Division of Molecular and Medical Genetics
, Center for Gene and Cell Therapy

The Institute of Medical Science, The University of Tokyo


Japanese

Novel application of genome editing tool CRISPR-Cas3 in gene therapy and diagnosis

Prof. Tomoji Mashimo

professor
Laboratory Animal Research Center
Institute of Medical Science, the University of Tokyo

Japanese

Yukoh Nakazaki

Board Director, CSO
HuLA immune Inc.

Japanese

Prof. Takeshi Wada


Japanese

Mr. Katsuaki Ura

Director
Division of Pharmaceutical Research and Development, Department of Innovative Drug Discovery and Development
Japan Agency for Medical Research and Development (AMED)

Japanese

Kouhei Tsumoto

Center for Drug Discovery Research, National Institutes of Biomedical Innovation, Health and Nutrition

Japanese


Oct.15(Fri.)      13  :  00  ~  14  :  30

F203-204
【O-14】
Pre-Registration required Video Archive available after Exhibition (subject to a fee)

Dx Implementation in the Pharmaceutical Industry 

Coordinator

Astellas Pharma Inc.

Acceleration of innovation creation by making DX "company-wide"

Ms. Satoko Shisai

General Manager of Digital & IT Supervisory Div., Vice President
CHUGAI PHARMACEUTICAL Co., Ltd.

Japanese

Digital Transformation in Astellas to "turn innovative science into VALUE for patients"

Mr. Shinya Suda

Senior Vice President, Information Systems
Information Systems
Astellas Pharma Inc

Japanese

Next Generation Engagement for our customer

Mr. Shin Tanaka

Head of Data and Digital Transformation & Head of Business Excellence Department (a.i.)
Oncology Division
Novartis Pharma K.K.

Japanese


Partnering Participants: Free
Visitor registration only: ¥10,000

Oct.13(Wed.)      13  :  30  ~  15  :  00

G401-402
【O-3】 Current status of manufacturing and expectations for supporting industries in regenerative medicine
Pre-Registration required Video Archive available after Exhibition (subject to a fee)

Current status of manufacturing and expectations for supporting industries in regenerative medicine  

Coordinator

Dr. Tohru Hirose

Forum for innovative regenerative medicine

Reality of Manufacturing Regenerative Medical Products and the Challenges in CDMO

Mr. Mori Yukio

Corporate Dfficer  Senior Manager, Production Engineering Department
Japan Tissue Engineering Co.,Ltd.

Japanese

Commercialization of regenerative medical products

Mr. Kenji Komeda

Senior Director
Regenerative and Cellular Medicine Manufacturing Plant
Sumitomo Dainippon Pharma Co., Ltd.

Japanese

Challenges facing the manufacturing of clinical-grade iPSC banks.

Dr. Masayoshi Tsukahara

Head
Research and Development Center
CiRA Foundation

Japanese


Partnering Participants: Free
Visitor registration only: ¥10,000

Oct.13(Wed.)      16  :  00  ~  17  :  00

F201-202
【S-5】 KSP, Inc.
Pre-Registration required

Activities of the RINK ~Building a network for industrialization of regenerative medicine and cell medicine that connects Kanagawa and the World~ 

The Regenerative medicine & Cell therapy industrialization network of Kanagawa (abbreviated as RINK) was established for the purpose of creating innovation through the mutual linking and collaboration of institutions involved in the regenerative medicine and cell therapy field, in order to promote the utilization and industrialization of regenerative medicine and cell therapy. In this session, we would like to introduce the latest innovation activities in regenerative medicine and cell medicine, and discuss the role that the RINK should do in building a network for industrialization of regenerative medicine and cell medicine that connects Kanagawa and the world.

Coordinator

Mr. Kenichi Harada

The Regenerative medicine & Cell therapy industrialization network of Kanagawa (RINK)

Mr. Makino Yoshiyuki

Kanagawa Prefectural Government

Japanese

Prof. Masaya Nakamura

Professor, Keio University School of Medicine / Director, K Pharma, Inc.

Japanese

Prof. Yasunori Aizawa

Associate Professor, School of Life Science and Technology, Tokyo Institute of Technology/ CEO, Logomix, Inc / Project Leader of KISTEC

Japanese

Mr. Ryuta Nomura

Chairman of the board Chief Executive Officer Central Institute for Experimental Animals (CIEA) / Chairman, KING SKYFRONT Network Council

Japanese

Mr. Kiichi Kubota

President and CEO, KSP, Inc.

Japanese

Mr. Yoshiya Kakizaki

Director, Osaka Sanitary Co., Ltd.

Japanese

The Regenerative medicine & Cell therapy industrialization network of Kanagawa (RINK)

Japanese

Mr. Kentaro Yamaguchi

Director, Kanagawa Prefectural Government

Japanese


Oct.14(Thu.)      9  :  30  ~  11  :  00

F205-206
【O-5】 Challenges for industrialization of Regenerative Medicine
Pre-Registration required

Challenges for industrialization of Regenerative Medicine 

Coordinator

Dr. Ken-ichiro Hata

Representative Director, Chairman
Forum for innovative regenerative medicine

Pharmaceutical Company’s Perspective: Current and Future Utilization of Registry

Mr. Taizo Fujita

Japan Pharmaceutical Manufacturers Association, Clinical Evaluation Expert Committee (Novartis Pharma K.K.)

Japanese

Industrialization of cell therapy products from the standpoint of hospital and academia

Prof. Nagamura-Inoue Tokiko

Clinical Professor / Deputy Director
Research Hospital, Department of Cell Processing and Transfusion/ IMSUT CORD
The Institute of Medical Science, The University of Tokyo

Japanese

Government Initiatives Toward Industrialization of Regenerative Medicine and Gene Therapy

Ms. Suzuka Mohri

Deputy Director
Bio-Industry Division
Ministry of Economy, Trade and Industry

Japanese


Oct.14(Thu.)      13  :  00  ~  14  :  00

F205-206
【S-12】 Minaris Regenerative Medicine Co, Ltd.
Pre-Registration required

Establishing Organization and global Quality for commercial manufacturing of Regenerative Medicine
-Minaris Regenerative Medicine as Global CDMO in Japan, US and Europe- 

In August 2021, Yokohama -site was the Split of Showa Denko Materials' Regenerative Medicine Business Sector as named Minaris Regenerative Medicine Co., Ltd.
We are in Showa Denko Materials Group operates a global regenerative medicine business at five facilities - one in Japan (Yokohama City, Kanagawa Prefecture),
three in the United States (one in Mountain View, California and two in Allendale, New Jersey), and one in Europe (Ottobrunn, Bavaria, Germany).
In September 2020, the Group's regenerative medicine companies in the United States and Germany changed their names to Minaris Regenerative Medicine, LLC and Minaris Regenerative Medicine GmbH, respectively.
With Yokohama Site taken over by MRJ, all the manufacturing facilities in Japan,
the United States, and Europe will be unified under the name "Minaris Regenerative Medicine"
The Showa Denko Materials Group will promote this name as the global brand of its contract manufacturing services for regenerative medicine products.
In this seminar, we would like to explain our view points for Establishing Organization and global Quality for commercial manufacturing of Regenerative Medicine.


Prof. Kazuchika Furuishi

Corporate Officer and General Manager, and CEO of Minaris Regenerative Medicine, LLC
Regenerative Medicine Business Sector
Showa denko Materials Co., Ltd and Minaris Regenerative Medicine, LLC

Japanese

Prof. Hiroto Bando

Deputy General Manager, and CEO of Minaris Regenerative Medicine Co.,Ltd.
Regenerative Medicine Business Sector
Showa denko Materials Co., Ltd and Minaris Regenerative Medicine Co., Ltd.

Japanese


Oct.14(Thu.)      16  :  10  ~  16  :  40

Main Stage
Regenerative Medicine Japan
Pre-Registration not required

Efforts of university-launched venture companies, from the field of regenerative medicine 

Coordinator

Mr. Hiroyuki Kano

The Forum for Innovative Regenerative Medicine (FIRM)

Mr. Kenichi Nogami

Co-Founder / Co-CEO
Metcela Inc.

Japanese

Mr. Kengo Ueha

Partner, Board Director
Beyond Next Ventures Inc.

Japanese

Oct.15(Fri.)      10  :  00  ~  11  :  30

F203-204
【O-13】
Pre-Registration required Video Archive available after Exhibition (subject to a fee)

iPS Cell Reserch and Development Update 

Regarding iPS cell research, which is being put to practical use, we will talk with the inventor, Professor Yamanaka, and President Takahashi of Vision Care, who is leading the practical use in the field of ophthalmology, and hold a panel discussion on issues and future prospects. This is a session to share with you the cutting edge of industrialization and research of iPS cells.

Coordinator

Prof. Miyata Mitsuru

CEO
Miyata Institute of Technologies,KK

【Remote Presentation】
Recent Progress in iPS Cell Research and Application

Prof. Yamanaka Shinya

Director/Professor
Center for iPS Cell Research and Application (CiRA), Kyoto University

Japanese

Retinal cell therapy and immune reaction

Dr. Masayo Takahashi

President
Vision Care Inc.

Japanese


Partnering Participants: Free
Visitor registration only: ¥10,000

Oct.15(Fri.)      15  :  30  ~  17  :  00

F205-206
【O-17】 Comparison of industry related to regenerative medicine in global
Pre-Registration required

Comparison of industry related to regenerative medicine in global 

Coordinator

Dr. Shitaka Yoshitsugu

Forum for innovative regenerative medicine

Global ecosystem related to cell & gene therapy and current challenges in Japan

Mr. Ryo Hanamura

Partner
Arthur D Little Japan

Japanese

What can Japan Learn from non-Japanese Cell/Gene Therapy Pricing Methodologies?

Mr. Colin Novick

Director
Innovacell K.K.

Japanese

Mr. Yoshihide Esaki

Institute for Social Policy Issues

Japanese


Oct.13(Wed.)      11  :  30  ~  13  :  00

G401-402
【O-1】 building a biotech-ecosystem, open to the world
Pre-Registration required

building a biotech-ecosystem, open to the world 

Japan has been a global source of innovation across many industries. In biotech, however, market growth has been staggered in the last decade, mainly due to the lack of platforms where strong start-ups are emerging and supported by risk money.
The size of the VC market in Japan is $1.23 billion in 2020, only 2.5% of the US market. The key challenge identified is that few ex-Japan VCs invest in Japanese start-ups, and the market is closed in Japan, while the global investment is centered in the US. Many startups are emerging from academia, industry, and through their collaborations in successful ecosystem. They are raising enormous funds, accelerating research & development and achieving exits through M&A or IPOs, supported by incubators and accelerators. On top, the government supports policies and regulations to promote innovation there. Talents, technologies, and funds are accumulated into such ecosystem.
In this session with venture capitalists, a biotech entrepreneur, and a government official, we would like to discuss what kind of problems we should tackle and how we can solve them to build a biotech ecosystem in Japan and invigorate the industry.

Coordinator

Dr. Fujimoto Toshio

General Manager
Shonan Health Innovation Park

Let's go fly, Japanese biotech!

Mr. Komoto Sheen

Partner
Eight Roads Ventures Japan

Japanese

Dr. BT Slingsby

Founder & Managing Partner
Catalys Pacific, LLC

Japanese

Our approach to global market

Mr. Hiroshi Miyake

President & CEO
Chordia Therapeutics Inc.

Japanese

Strategy for accelerating the growth of the biotech startup ecosystems

Mr. Kozo Saiki

Director, Bio-Industry Division
Commerce and Service Industry Policy Group
Ministry of Economy,Trade and Industry

Japanese


Oct.14(Thu.)      10  :  30  ~  11  :  30

【S-26】 The National Institute of Advanced Industrial Science and Technology (AIST)
Pre-Registration required Online Seminar

Exploratory healthcare researches by AIST 

Social needs related to healthcare are increasingly diversifying. To help support the medical system and improve QoL, AIST is developing new technologies that contribute to the diagnosis and treatment of diseases and the extension of healthy life expectancy on all scales from molecules to cells and to individuals. In this online seminar, we will introduce highly original studies conducted by 6 young and up-and-coming researchers in the Department of Life Science and Biotechnology.

Biomaterials for fabricating designered cells

Dr. Yuji TERAMURA

Senior Researcher
Cellular and Molecular Biotechnology Research Institute, AIST

Japanese

Simultaneous analysis of glycan and RNA in single cells

Dr. Haruki Odaka

Researcher
Cellular and Molecular Biotechnology Research Institute, AIST

Japanese

A simple technique to measure intracellular singlet oxygen

Dr. Kazutoshi Murotomi

Senior Researcher
Biomedical Reseach Institute, AIST

Japanese

Raman spectroscopy system for single cell analysis

Dr. Yuka Akagi

Researcher
Cellular and Molecular Biotechnology Research Institute, AIST 、Advanced Photonics and Biosensing Open Innovation Laboratory

Japanese

Elucidation of bile salt resistance mechanism in a thermostable probiotic lactic acid bcterium

Dr. Hiroyuki KUSADA

Researcher
Bioproduction Research Institute, AIST

Japanese

Development of Preventiion Methods for Alzheimer's Disease

Dr. Saori Hata

Senior Researcher
Biomedical Reseach Institute, AIST

Japanese


Oct.14(Thu.)      12  :  00  ~  13  :  30

G403-404
【O-18】 Creation and commercialization of measurements x AI platform for the science of health
Pre-Registration required Video Archive available after Exhibition (subject to a fee)

Creation and commercialization of measurements x AI platform for the science of health 

In the wake of the global spread of the new coronavirus disease, new sensing technologies based on digital technology have been attracting attention. With the advancement of technology, sensors and testing equipment have become smaller, lighter, and more versatile, making it easier for anyone to acquire a variety of data.
In this session, we will focus on products and services that are strategic in terms of "cultivating and expanding ultra-small-signal measurement technology" and "utilizing the acquired data," which are the keys to the future development of the healthcare industry.

Coordinator

Prof. Tsuyoshi Sekitani

Professor
The Institute of Scientific and Industrial Research
Osaka University

Development of biosensing for e-healthcare

Prof. Eiichi Tamiya

Director
Advanced Photonics and Biosensing Open Innovation Laboratory
National Institute of Advanced Indutrial Science and Technology

Japanese

Mr. Makoto Tada

CEO Ofice

Japanese

Exosome Biomarker Platform

Mr. Ryuichi Onose

Chief Executive Officer
Craif Inc.

Japanese

Electrochemical immunoassay "GLEIA" opens the way to the future of POCT

Mr. HIROKAZU SUGIHARA

CEO
HQ
IMMUNOSENS CO., LTD.

Japanese

Maximizing the information values of brainwave data

Mr. Hideki Matsubara

President and Representative Director
PGV Inc.

Japanese


Partnering Participants: Free
Visitor registration only: ¥10,000

Oct.14(Thu.)      13  :  30  ~  14  :  30

F203-204
【S-19】 Johnson & Johnson Innovation
Pre-Registration required Simultaneous interpretation

【Johnson & Johnson Innovation Seminar】 Fostering Flexible Collaboration Opportunities to Support a Thriving Life Science Ecosystem 

At Johnson & Johnson Innovation, we know that a great idea can come from anywhere and we are proud of our strong track record of sourcing and partnering to bring forward the most promising early-stage healthcare innovation wherever it originates.

In this seminar, we combine Johnson & Johnson Innovation leaders with strategic partners and collaborators from the Japanese ecosystem to reflect on successful experiences and forward-looking opportunities that will further strengthen our commitment to build a strong life science ecosystem in Japan and the world.

Driving Early Innovation Partnerships in Japan and Asia Pacific

Dr. Jun Kusunoki

Director, Country Lead- Japan
Early Innovation Partnering
Johnson & Johnson Innovation - Asia Pacific

Japanese

【Fireside Chat】 Fostering Flexible Collaboration Opportunities to Support a Thriving Life Science Ecosystem

Dr. Dan Wang

Regional Head
Johnson & Johnson Innovation - Asia Pacific

Dr. Toshio Fujimoto

General Manager
Shonan Health Innovation Park

【Panel Discussion】 Exploring Opportunities and Breaking Barriers as an Early-stage Researcher

Dr. Jun Kusunoki

Johnson & Johnson Innovation, Asia Pacific

Japanese

Dr. Shinichi Kondo

Director, Pipeline Sustainability & Partnership
Research, Neuroscience Drug Discovery Unit
Takeda Pharmaceutical Co., Ltd.

Japanese

Dr. Takahisa Murata

Associate Professor
Graduate School of Agricultural and Life Sciences
The University of Tokyo

Japanese

Dr. Naoyuki Masuda

CEO
Nexuspiral Inc.

Japanese

Mr. Tomotsugu Ohashi

Alliance Manager, Japan
Johnson & Johnson Innovation - Asia Pacific

Japanese


Oct.14(Thu.)      13  :  30  ~  14  :  30

G401-402
【S-11】 UTokyo Innovation Platform Co., Ltd.
Pre-Registration required

2021 Mid-Year Life Science Venture Overview - What’s next from the trends? - 

Together with the global professionals in the Japanese venture community, we will discuss the upcoming trends in the post-pandemic future.

Coordinator

Makoto (Mark) Ohori

Partner, Chief Investment Officer, Life Science
The University of Tokyo Innovation Platform Company (UTokyo IPC)

【Welcome & Introduction to UTokyo IPC】

Mr. Katsuhiko Oizumi

President and CEO
The University of Tokyo Innovation Platform Company (UTokyo IPC)

Japanese

【Panel Discussion】
2021 Mid-Year Life Science Venture Overview - What’s next from the trends? -

Makoto (Mark) Ohori

The University of Tokyo Innovation Platform Company (UTokyo IPC)

Japanese

[Featured Review] Biotech VC Investment Trend

Sakae Asanuma

President & CEO
Taiho Ventures, LLC

Japanese

Hiroki Ashida

Senior Associate
Eight Roads Ventures Japan

Japanese

Takehiko Kaneko

Director of the Board, Chief Medical Officer, Head of R&D
Heartseed Inc.

Japanese

Toru Kanke

CEO
LiberoThera Company Limited

Japanese

Chika Hashimoto

President
Gallasus LLC

Japanese

Toshiyuki Mori

CEO
TM Partners LLC

Japanese


Oct.14(Thu.)      14  :  30  ~  15  :  30

F205-206
【S-16】 Shonan Health Innovation Park
Pre-Registration required

Cultivating a Collaborative Space for Health Innovation - Real Voices from the Life Science Ecosystem Players 

In the three and a half years since its opening, Shonan Health Innovation Park, which started with 19 companies as tenants, has grown into an open innovation hub where more than 120 companies and academia have gathered. One of the characteristics of the ecosystem is the participation of a wide variety of players, including major pharmaceutical companies, drug discovery ventures, equipment manufacturers, academia, local government, and VCs, as well as the presence of more than 1,000 life science researchers.
In this seminar, we will introduce Shonan iPark's efforts to lead and support the exploration, co-creation, and drive, as well as the new businesses and initiatives that have been created as a result of these efforts. In addition, the key players of Shonan iPark will gather to share their real voices at the forefront of the field, including what they are doing and what they feel are the challenges to create greater health innovation in the future.

Coordinator

Dr. Fujimoto Toshio

General Manager
Shonan Health Innovation Park

Dr. BT Slingsby

Founder, Managing Partner
Catalys Pacific, LLC

Japanese

Dr. Aruto Yoshida

General Manager
Kirin Central Research Institute
Kirin Holdings Company, Limited

Japanese

Dr. Rikako Yamauchi

Vice President, Head of Research Unit/Frontier Sohyaku
Innovative Research Division
Mitsubishi Tanabe Pharma Corporation

Japanese

Dr. Kenji Nonaka

President, Representative Director and CEO
Orizuru Therapeutics Inc.

Japanese

Dr. Nobuhiko Kojima

Associate Professor
Regenerative Biology Laboratory, Graduate School of Nanobioscience
Yokohama City University

Japanese


Oct.15(Fri.)      9  :  30  ~  11  :  30

F201-202
【O-11】 Functional Food supports healthy and longevity society ~Important for Frailty Prevention to happy aged-life~
Pre-Registration required

Functional Food supports healthy and longevity society ~Important for Frailty Prevention to happy aged-life~ 

We are running into Super-aging society Japan.We convince that we need a social foundation that will realize a mature and mellow process that is both physically and mentally sound throughout our lives.
Food plays a great role in the social infrastructure, and it is sure that "food" is good for health and longevity so that it does not become a state of flail, which is regarded as a phenomenon of a eakening entrance rather than maturity.
We will disseminate information and opinions on the expected role of "healthy food", including the direction in which the health functional food system should be developed, in order to build an environment that can appeal globally.

Coordinator

Prof. Teruo Miyazawa

Professor and Project Leader
Tohoku University, New Industry Creation Hatchery Center

Prof. Katsuya Iijima

Profgessor
Institute for Future Initiatives
TOKYO University, Institute of Gerontology

Japanese

Happy aging: mental health and frailty

Dr. Masayo Kojima

Department Head
Department of frailty research
National Center for Geriatrics and Gerontology

Japanese

Importance of dietary habit for frailty measures: What should we focus on for the older adults?

Ms. Kinoshita Kaori

research fellow
Department of Frailty Research, Center for Gerontology and Social Science
National Center for Geriatrics and Gerontology

Japanese

Relation between Frailty and Immune System ~ Role of Functional Foods on Gut Function ~

Prof. Kazunaga Yazawa

Profgessor
Research organization for Nano & Life innovation
WASEDA University

Japanese


Oct.15(Fri.)      11  :  30  ~  12  :  30

F205-206
【S-17】 JETRO Kyoto
Pre-Registration required

Connecting with Boston's Ecosystem - The Role of BioLabs
/Panel Discussion 

【Seminar】The value that BioLabs brings to Japanese ecosystem

Mr. Kuroda Taruho (Panelist)

Japan Liaison
BioLabs Global Inc.

Japanese

Prof. Tomoyoshi Koyanagi(Moderator)

Professor
Faculty of Medicine, University of Tsukuba

Japanese

Mr. Haru Morita (Panelist)

President and CEO
Modalis Therapeutics

Japanese

Mr. Tai Harada (Panelist)

Vice President
Fast Track Initiative

Japanese

Introduction of Life Science Startup Support Program by JETRO

Ms. Kato Saki

JETRO Kyoto

Japanese


Oct.15(Fri.)      15  :  00  ~  16  :  30

F201-202
【O-16】 Role of exercise in healthy aging ~Unraveling the superactive senior~
Pre-Registration required

Role of exercise in healthy aging ~Unraveling the superactive senior~ 

Due to the outbreak of COVID-19, there has been a tendency to refrain from going out for the purpose of infection prevention. In Japan, a state of emergency was declared four times, and restraint from activities involving going out was recommended, especially in metropolitan areas. Even in the absence of emergency declarations, it is clear that physical activity among older people is declining, and this is reflected in an increase in frailty. Such self-restraint in activity leads to a drastic reduction in not only physical activity but also social interaction, resulting in a decline in physical and cognitive functions. There is a concern that the number of disabled older people will increase due to the progression of sarcopenia and frailty, as well as the deterioration of cognitive function. In this situation as well as the aging of the population, it is necessary to balance infection prevention and activity, exercise outdoors and at home, and nutritional intake that maintains an appropriate balance. To further extend healthy life expectancy, it is necessary to establish appropriate exercise habits, but it is also important to build scientific evidence. We hope that national awareness of exercise will lead to the extension of healthy life expectancy.

Coordinator

Dr. Hidenori Arai

President
National Center for Geriatrics and Gerontology

Implication of Exercise in Healthy Longevity -View Point of Frailty Prevention-



Prof. Suzuki Takao


Japanese

Development of Healthy Society through Sports

Prof. Ken Nakata

Professor
Graduate school of Medicine Medicine for Sports and Performing Arts
Osaka University

Japanese

Does exercise really make you healthier?

Dr. Kojiro Ishii

professor
Faculty of Health & Sports Science
Doshisha University

Japanese


【S-25】 New Energy and Industrial Technology Development Organization
Pre-Registration required Online Seminar

The contribution and potential of biotechnology for the realization of a sustainable society 

NEDO believes that it is important to promote, in an integrated and organic manner, three social systems to realize a sustainable society. The three systems are a "circular economy", a "bioeconomy", and "sustainable energy". In this issue, we will introduce the research and development projects that are responsible for each social system from the perspective of biotechnology. We will also consider the contribution and potential of biotechnology in solving climate change issues and realizing a society that continues to develop in a sustainable manner.

Coordinator

Mr. Wataru Mizunashi

Technology Strategy Center
New Energy and Industrial Technology Development Organization

Outline of Moonshot Goal 4, which aims to realize sustainable resource circulation to recover the global environment, and expectations for biotechnology

Hiroyuki Yamada

Director
Frontier and Moonshot Tnechnology Department
New Energy and Industrial Technology Development Organization

Japanese

Expectations and challenges of "Bio" in the sustainable energy field
-Focusing on SAF (Sustainable Aviation Fuel) production-

Toshiaki Kimura

Project Coordinator
New Energy Technology Department
New Energy and Industrial Technology Development Organization

Japanese

Latest trends and future prospects in the bio-economy area

Mr. Toshiya Imada

Materials Technology and Nanotechnology Department
New Energy and Industrial Technology Development Organization

Japanese


Oct.13(Wed.)      13  :  30  ~  15  :  30

F205-206
【S-3】 New Energy and Industrial Technology Development Organization
Pre-Registration required

The contribution and potential of biotechnology for the realization of a sustainable society 

NEDO believes that it is important to promote, in an integrated and organic manner, three social systems to realize a sustainable society. The three systems are a "circular economy", a "bioeconomy", and "sustainable energy". In this issue, we will introduce the research and development projects that are responsible for each social system from the perspective of biotechnology. We will also consider the contribution and potential of biotechnology in solving climate change issues and realizing a society that continues to develop in a sustainable manner.

Coordinator

Mr. Wataru Mizunashi

Director General Bioeconomy Unit
Technology Strategy Center
New Energy and Industrial Technology Development Organization (NEDO)

Outline of Moonshot Goal 4, which aims to realize sustainable resource circulation to recover the global environment, and expectations for biotechnology

Dr. Hiroyuki YAMADA

Director General
Frontier and Moonshot Tnechnology Department
New Energy and Industrial Technology Development Organization (NEDO)

Japanese

Expectations and challenges of "Bio" in the sustainable energy field
-Focusing on SAF (Sustainable Aviation Fuel) production-

Dr. Toshiaki KIMURA

Project Coordinator
New Energy Technology Department
New Energy and Industrial Technology Development Organization (NEDO)

Japanese

Latest trends and future prospects in the bio-economy area

Mr. Toshiya imada

Director General
Materials Technology and Nanotechnology Department
New Energy and Industrial Technology Development Organization (NEDO)

Japanese


Oct.13(Wed.)      14  :  30  ~  15  :  30

F201-202
【S-4】 The National Institute of Advanced Industrial Science and Technology (AIST)
Pre-Registration required

Driving the Global Bioeconomy with Genomics 

AIST is carrying out research and development with various approaches to realize bioeconomy society. In this seminar, we Department of Life Science and Biotechnology will introduce our recent studies using genomics approaches to advance the global bioeconomy, such as the development of an innovative technology for the derivatization of natural compounds, a new method based on network modeling to propose candidate microbial genes for the promotion of microbial engineering, and an advanced technology to introduce proteins into plant cells for genome editing.

Coordinator

Dr. Yasunori Chiba

Director
Reserch Planning Office,Department of Life Science and Biotechnology
AIST

Innovative technology for the production of natural compounds and its derivatives (application for drug development)

Dr. Kazuo Shin-ya

Group Leader
Cellular and Molecular Biotechnology Research Institute, AIST

Japanese

Effectiveness of Network Modeling for Microbial Breeding

Dr. Sachiyo Aburatani

Vice Director
AIST-Waseda University Copmutational Bio-Big Data Open Innovation Laboratory

Japanese

Intracellular delivery of genome editing proteins

Dr. Yoshio Kato

Group Leader
Biomedical Research Institute, AIST

Japanese


【S-24】 National Institute of Technology and Evaluation
Pre-Registration required Online Seminar

Value creation to the fields of healthcare and manufacturing
- Accelerating data collaboration and data utilization in the field of biotechnology - 

The biotechnology industry is transforming into a data-driven industry with the digital revolution that produces large amounts of data and advances in analytical technology.
In this seminar, two experts will introduce future prospects for the realization of the world's most advanced bio-economy society, while introducing the infrastructure for data utilization in Japan's biotechnology field and examples applied to innovative manufacturing. In addition, we will introduce the construction of the "Data and Biological Resource Platform (DBRP)", a platform that integrates biological resource data for the development of data-driven industries.

「The future of biotechnology driven by digital information」

Dr. Shinichiro Kato

Director-General
Biological Resource Center, NITE (NBRC)
National Institute of Technology and Evaluation

Japanese

「Collection, analysis and integration of human intestinal environment data for utilization in the healthcare research」

Dr. Jun Kunisawa

Director
Center for Vaccine and Adjuvant Research
National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN)

Japanese

「New era of providing microbe and data ~infrastructure development by DBRP~」

Dr. Natsuko Ichikawa

Director, Bio-Digital Transformation Office, Administrative Affairs Division
Biological Resource Center, NITE (NBRC)
National Institute of Technology and Evaluation

Japanese

「Realization of an Integrated Biofoundry by fusing Synthetic Biotechnology and Digital Technology」

Prof. Akihiko Kondo

Professor
Graduate School of Science, Technology and Innovation
Kobe University

Japanese


Oct.13(Wed.)      15  :  30  ~  17  :  00

G401-402
【O-4】 Data governance: its importance in digital healthcare
Pre-Registration required Simultaneous interpretation Video Archive available after Exhibition (subject to a fee)

Data governance: its importance in digital healthcare 

In a super-aging society it has become an important issue to improve QOL of the elderly, and to optimize social security costs. Companies utilizing big data for digital health care are required to master DATA GOVERNANCE.

Coordinator

Prof. Makoto Suematsu

Professor
School of Medicine
Keio University

Global data sharing: A challenge emerging in COVID-19 era

Prof. Makoto Suematsu

【Remote Presentation】
The Future of Health is Connected - How to bring together our solutions and ecosystem for seamless experiences and outcomes from anywhere

Mr. Keiichi Sato

Senior Director, Financial Services and Healthcare Industry
Industries Transformation
Salesforce

Japanese

Creating new healthcare business through utilization of personal health record

Mr. Takuma Inamura

Director ,Healthcare Industries Division
Commerce and Service Industry Policy Group
Ministry of Economy, Trade and Industry

Japanese

【Remote Presentation】
What is Data Governance and Why it Matters

Dr. Evren Eryurek

Director of Product Management at Google


Partnering Participants: Free
Visitor registration only: ¥10,000

Oct.14(Thu.)      15  :  00  ~  16  :  30

G403-404
【O-10】 Business Strategy of Digital Therapeutics (DTx)
Pre-Registration required Video Archive available after Exhibition (subject to a fee)

Business Strategy of Digital Therapeutics (DTx) 

Coordinator

Dr. Toru Kimura

Representative Director, Executive Vice President, CSO
Sumitomo Dainippon Pharma Co., Ltd.

Medical practice and medical research using digital technology

Dr. Ueno Taro

CEO
SUSMED Inc

Japanese

Digital therapy and person centred care for dementia

Dr. Nick Hird

CEO and Co-founder
Aikomi

Japanese

Digital Therapeutics: Current status and Future

Mr. Yoshinori Satomi

Director
Digital Intelligence Department, DX Promotion Division
Shionogi & Co. LTD.

Japanese

Mr. Noriatsu Kono

Chief Management Officer
Pharmaceuticals and Medical Devices Agency

Japanese


Partnering Participants: Free
Visitor registration only: ¥10,000

【S-23】 GenScript Japan, Inc.
Pre-Registration required Online Seminar

GCT Outsourcing Success Factors 

Gene and cell therapy (GCT) has the potential to transform medicine by providing long-term, curative treatments for a variety of diseases. GenScript ProBio is developing a GMP platform for the delivery of viral and non-viral vectors. In this seminar, we will introduce how exactly we can make outsourcing a success.

GCT Outsourcing Success Factors

Mr. CHU Fredy

Head of Quality
GenScript ProBio ( CDMO segment )
GenScriptJapan KK


Oct.13(Wed.)      12  :  00  ~  13  :  30

G403-404
【O-2】 Opening up the new business horizon with bio-technology driven innovation collaboration of industry-government-academia to realize bio-economy
Pre-Registration required

Opening up the new business horizon with bio-technology driven innovation collaboration of industry-government-academia to realize bio-economy 

Coordinator

Mr. Naoto Yabe

Executive Director, Division General Manager, Innovation and Entrepreneurship Division
Innovation and Entrepreneurship Division
Mitsubishi Chemical Corporation

About NEDO Bio Manufacturing Project for Realization of Carbon Recycling (tentative title)

Prof. Minoru Seki

Professor
Graduate School of Engineering
Chiba University

Japanese

Realization of a resource-cycle society through Biotechnology ~Waste to Plastic with Bio~

Mr. Satoshi Koma

Senior Manager
New Business Development Department BR Business Group
Sekisui Chemical Co.,Ltd.

Japanese

Plant-Based Food,Now in the Spotlight

Mr. Shigeru Ashida

Soy ingredients Business Division
FUJI OIL CO., LTD.

Japanese

CircularBio ™ Business Project -Green chemical production from new "ground resources"-

Green Earth Institute Co., Ltd.

Japanese


Oct.14(Thu.)      9  :  30  ~  11  :  30

G403-404
【O-6】 Toward the realization of carbon neutral in 2050
Pre-Registration required Video Archive available after Exhibition (subject to a fee)

Toward the realization of carbon neutral in 2050 

With the return of the United States to the Paris Agreement, the movement toward decarbonization of the world has accelerated at a stretch, and each country has launched a new strategy, seeing it as an opportunity to grow and gain international competitiveness. Japan has also declared that "Greenhouse gas emissions will be virtually zero by 2050" and the sense of crisis and momentum in the industrial world has increased. In this seminar, we will introduce the Japanese strategy of policy, management, Research and Development, as well as understanding the international situation of decarbonization.

Coordinator

Prof. Kuniki Kino

Professor
Faculty of Science and Engineering
Waseda University

Mr. Nakai Tokutaro

Vice-Minister of the Environment
Ministry of the Environment

Japanese

NEDO’s activities to carbon neutrality in 2050

Mr. Hiroaki ISHIZUKA

Chairman
New Energy and Industrial Technology Development Organization

Japanese


Responsibilities and contributions of chemical industry to realize carbon neutrality

Mr. Junpei Tsuji

Associate Officer ①General Manager ②Secretary-general
①Research Planning & Coordination Dept.  ②Carbon Neutral Strategy Council
Sumitomo Chemical Co., Ltd

Japanese

Sustainability Strategy of Ajinomoto Group – Countermeasures to climate change



Ms. Chika Morishima

Executive Officer, In charge of Sustainability and Communication
Ajinomoto Co., Inc.

Japanese


Partnering Participants: Free
Visitor registration only: ¥10,000

Oct.14(Thu.)      15  :  00  ~  16  :  30

F201-202
【O-8】 How can we make useful compounds in "decarbonization society" through renewable energy and/or carbon dioxide utilization?
Pre-Registration required

How can we make useful compounds in "decarbonization society" through renewable energy and/or carbon dioxide utilization? 

Even in a "decarbonization society", manufacturing based on carbon skeleton should continue to be important. This indicates the need to further advance manufacturing based on renewable energy or/or carbon dioxide. Therefore, in this program, we would like to introduce the cutting edge of such research field and view the future manufacturing in a "decarbonization society".

Coordinator

Prof. Ishii Masaharu

Professor
Graduate school of Agricultural and Biological Sciences
The University of Tokyo

Current status and prospects of biomanufacturing to realize a carbon-neutral society

Prof. Masayuki Inui

Group Leader, Chief Researcher
Molecular Microbiology and Biotechnology Group
Research Institute of Innovative Technology for the Earth

Japanese

Technologies for CO2 fixation by combination of life science and material science

Dr. Souichiro Kato

Senior researcher
Bioproduction Research Institute
National Institute of Advanced Industrial Science and Technology

Japanese

Sustainable bio-production from CO2 by electricity derived from renewable energy

Dr. Shin-ichi Hirano

Senior Research Scientist
Biology and Environmental Chemistry Division, Sustainable System Research Laboratory
Central Research Institute of Electric Power Industry

Japanese

Development of Algae-Based Bio Jet Fuel

Mr. Tomoo Mizuno

Associate Director, Head of Algae^Based Biofuel Group
IHI Corporaion

Japanese


Oct.13(Wed.)      14  :  00  ~  16  :  45

G403-404
【A-1】 Japan Bioindustry Award, Bioindustry Research Award 2021 Ceremony and Award Lecture
Pre-Registration required

Japan Bioindustry Award・Bioindustry Research Award 2021 Ceremony and Award Lecture
14:00-14:50 Ceremony
15:00-16:45 Award Lecture 

Japan Bioindustry Award「Pioneering Research on Systems Biology and their Industrialization for Regional Promotion」

Dr. Masaru Tomita

Director General / Professor
Institute for Advanced Biosciences / Faculty of Environment and Information Studies
Keio University

Japanese

Japan Bioindustry Special Award「Creation, Industrialization, and Medical Applications of Biomimetic Biocompatible Polymers」

Dr. Kazuhiko Ishihara

Emeritus Professor, The University of Tokyo / Specially Appointed
Professor, Division of Materials and Manufacturing Science, Graduate School of Engineering, Osaka University

Japanese

Bioindustry Research Award「Unraveling the molecular network of parthenocarpy and its application for labor saving in tomato production」

Dr. Tohru Ariizumi

Associate Professor
Faculty of Life and Environmental Sciences
University of Tsukuba

Japanese

Bioindustry Research Award「Ghost cytometry and its applications」

Dr. Sadao Ota

Associate Professor
Research Center for Advanced Science and Technology, Networked biophotonics and microfluidics group
The University of Tokyo

Japanese

Bioindustry Research Award「Elucidation of molecular mechanisms of plant organ regeneration and its application to the development of basic technology for clonal propagation」

Dr. Misato Ohtani

Associate Professor
Graduate School of Frontier Sciences
The University of Tokyo

Japanese

Bioindustry Research Award「Research on the application and development of near infrared photoimmunotherapy」

Dr. Kazuhide Sato

Designated Assistant Professor (selected-YLC program)
Nagoya University Institute for Advanced Research (IAR) / School of Medicine, Dept of Respiratory Medicine
Nagoya University

Japanese

Bioindustry Research Award「New neuromuscular co-culture models for disease research and drug screening」

Dr. Kazunori Shimizu

Associate Professor
Department of Biomolecular Engineering, Graduate School of Engineering
Nagoya University

Japanese

Bioindustry Research Award「Development of rapid screening test for dementia using eye-tracking technology」

Dr. Shuko Takeda

Associate Professor
Clinical Gene Therapy
Osaka University Graduate School of Medicine

Japanese

Bioindustry Research Award「Elucidation of molecular and cellular mechanisms underlying taste perception」

Dr. Akiyuki Taruno

Professor
Department of Molecular Cell Physiology, Graduate School of Medical Sciences
Kyoto Prefectural University of Medicine 

Japanese

Bioindustry Research Award「Innovative purification methods of proteins and cells using functional interfaces」        

Dr. Kenichi Nagase

Associate Professor
Faculty of Pharmacy
Keio University

Japanese

Bioindustry Research Award「Studies of sustainable production and spinning mechanisms of spider silks」

Dr. Keiji Numata

Professor
Department of Material Chemistry
Kyoto University 

Japanese

Bioindustry Research Award「Grafting technology for sustainable use of plant resources」

Dr. Michitaka Notaguchi

Associate Professor
Bioscience and Biotechnology Center
Nagoya University

Japanese

Bioindustry Research Award「Development of locus-specific chromatin immunoprecipitation technologies and their applications」

Dr. Toshitsugu Fujita

Associate professor / Research Professor
Department of Biochemistry and Genome Biology
Hirosaki University Graduate School of Medicine  

Japanese

Bioindustry Research Award「Development of comprehensive single-cell genome analysis method for uncultured microbe community」 

Dr. Masahito Hosokawa

Associate Professor
Graduate School of Advanced Science and Engineering
Waseda University                           

Japanese


Oct.13(Wed.)      15  :  00  ~  16  :  30

Main Stage
【E-1】
Pre-Registration not required

【Main Stage A】 Promotion of Japan Bioeconomy-Strategy (1) -Three Years of the Bioeonomy-Strategy and Future Prospects 

In order to realize the world's most advanced bioeconomy society in 2030, Japan bioeconomy-strategy has been positioned as a policy and is being promoted by the public and private sectors with the Cabinet Office as the commander-in-chief. In this session, we will review the progress made so far from 2019 and discuss the future direction of the strategy.
In this session, we will review the progress made so far since 2019 and discuss future activities.

Coordinator

Dr. Hitoshi Kuboniwa

Japan Bioindustry Association

Grand design including data strategy in the healthcare field to enhance drug discovery

Mr. Yoshizawa Nao

GRiT Partners Law office

Japanese

【Remote Presentation】
Transforming Daiichi Sankyo to Biologics company

Junichi Koga

Senior Advisor
Daiichi Sankyo Co., Ltd

Japanese

Executive Director, Division General Manager, Innovation and Entrepreneurship Division
Mitsubishi Chemical Corporation

Japanese

Japan’s Bioeconomy Strategy’s Featuring Points

Mr.

Deputy Director General
Secretariat of Science, Technology and Innovation Policy
Cabinet Office

Japanese

Oct.14(Thu.)      10  :  30  ~  12  :  30

Main Stage
【E-2】 Create Bio-communities in Japan
Pre-Registration not required

【Main Stage A】Create Bio-communities in Japan 

Speedy R&D to market introduction with investment by gathering large companies, startups and investors under one roof.
Established recognition system to virtually create under roof bio-community and attract human resources and investment to provide new products and services.
Create Global Bio-communities in Tokyo and Kansai (Kyoto, Osaka and Hyogo) by the end of FY2021.
Created Regional Bio-communities in June in four unique regions (Hokkaido, Tsuruoka, Nagaoka and Fukuoka) as a start and will expand.
Form bio-clusters nationwide and build unique value chains in respective areas.

Coordinator

Mr. Takafumi Kakudo

Deputy Director General
Science, Technology and Innovation Policy
Cabinet Office

Cabinet Office

Japanese

Hokkaido Prime Bio-community
 - To Aim for Robust Primary-industry -

Prof. Kiyohiro Houkin

President
Hokkaido University

Japanese

Tsuruoka Science Park makes Japan exciting

Prof. Masaru Tomita

Director General
Institute for Advanced Biosciences, Keio University

Japanese

Nagaoka Bio Community~Aiming for a bio-community with complete recycle of local resources 

Mr. Tatsunobu Isoda

Mayor of Nagaoka
Nagaoka City

Japanese

Characteristics and future image of Fukuoka bio-community
~ Challenge to the Kurume ecosystem ~

Mr. Okubo Tsutomu

Mayor
Kurume City

Japanese

Towards Formation of the Greater Tokyo Biocommunity

Mr. Nagayama Osamu

Greater Tokyo Biocommunity Council, Chairman (Chugai Pharmaceutical Co., Ltd. Honorary Chairman)

Japanese

Formation and Efforts of Bio-community Kansai (BiocK)

Dr. SAKATA TSUNEAKI

Deputy Chairman
Bio-community Kansai (BiocK)

Japanese

Oct.15(Fri.)      15  :  00  ~  17  :  00

F203-204
【S-15】 Japan Agency for Medical Research and Development
Pre-Registration required

The Human Frontier Science Program and the transformative power of basic scientific research to change society 

From human frontier science towards health care as a global sustainability industry

Prof. Pavel KABAT

Secretary General
International Human Frontier Science Program Organization

The Aim of AMED and the Significance of HFSP - The Essence of Interdisciplinary Fusion and International Collaboration

Dr. Yoshinao MISHIMA

International Human Frontier Science Program Organization Trustee
  Japan Agency for Medical Research and Development President / 

Japanese

Fun to Basic Science

Prof. Shigekazu NAGATA

International Human Frontier Science Program Organization President
OSAKA UNIVERSITY Immunology Frontier Research Center Distinguished Professor / 

Japanese

Cutting edge interdisciplinary research for a challenge at the frontier of nano-bioscience

Prof. Keiichi NAMBA

Specially Appointed Professor
Graduate School of Frontier Biosciences
OSAKA UNIVERSITY

Japanese

Next-generation RNA technology accelerated by international research

Prof. Hirohide SAITO

Deputy Director, Professor
Center for iPS Cell Research and Application
Kyoto University

Japanese

Turn innovative science into VALUE for patients

Dr. Taro MASUNAGA

Executive Vice President
Discovery Accelerator
Astellas Pharma Inc

Japanese

New Drug Creation and Basic Research

Dr. Hitoshi KUBONIWA

Japan Bioindustry Association  Chairman of the Steering Committee
CHUGAI PHARMACEUTICAL CO., LTD.  Advisor /

Japanese